A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation.

"Declarations Conflict of interestAny financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows; (1) those from which the authors, the spouse, partner or immediate relatives of authors, have received individually any income, honoraria or any other types of remuneration; Abbvie GK, EA Pahrma Co., Ltd, Janssen Pharmaceutical K.K, Mochida Pharmaceutical Co., Ltd, Tanabe Mitsubishi Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Kyorin Pharmaceutical Co., Ltd, Pfizer Japan Inc. and Kissei Pharmaceutical Co., Ltd, Nichi-iko Paermaceutical Co., Ltd, JIMRO Co., Ltd and (2) those from which the academic institutions of the authors received support (commercial/academic cooperation); Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Abbvie GK, EA Pahrma Co., Ltd, Eisai Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd, Nippon Kayaku Co., Ltd, Mochida Pharmaceutical Co., Ltd, Tanabe Mitsubishi Pharmaceutical Co., Ltd, Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd, EP-CRSU Co,. Ltd, ZERIA Pharmaceutical Co., Ltd, Alfresa Pharma Co. Ltd, JIMRO Co., Ltd. Daichi-Sankyo Co., Ltd, Kyorin Pharmaceutical Co., Ltd. Conflict of interest Any financial relationship with enterprises, businesses or academic institutions in the subject matter or materials discussed in the manuscript are listed as follows; (1) those from which the authors, the spouse, partner or immediate relatives of authors, have received individually any income, honoraria or any other types of remuneration; Abbvie GK, EA Pahrma Co., Ltd, Janssen Pharmaceutical K.K, Mochida Pharmaceutical Co., Ltd, Tanabe Mitsubishi Pharmaceutical Co., Ltd, Takeda Pharmaceutical Co., Ltd, Kyorin Pharmaceutical Co., Ltd, Pfizer Japan Inc. and Kissei Pharmaceutical Co., Ltd, Nichi-iko Paermaceutical Co., Ltd, JIMRO Co., Ltd and (2) those from which the academic institutions of the authors received support (commercial/academic cooperation); Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Abbvie GK, EA Pahrma Co., Ltd, Eisai Co., Ltd, Otsuka Pharmaceutical Co., Ltd, Kissei Pharmaceutical Co., Ltd, Nippon Kayaku Co., Ltd, Mochida Pharmaceutical Co., Ltd, Tanabe Mitsubishi Pharmaceutical Co., Ltd, Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd, EP-CRSU Co,. Ltd, ZERIA Pharmaceutical Co., Ltd, Alfresa Pharma Co. Ltd, JIMRO Co., Ltd. Daichi-Sankyo Co., Ltd, Kyorin Pharmaceutical Co., Ltd."

"This study was funded and carried out within the framework of a study project undertaken by the Study Group on Intractable Diseases, the Health and Labour Sciences Research Grants (chief researchers: Dr Y. Suzuki and T. Hisamatsu) from the Ministry of Health, Labor and Welfare of Japan."